Table 5.
2 Weeks Post-Commencement of MS/Mimotopic Peptide Therapy
| Epitope-Specific Serum IgE Signal: | |||
|
| |||
| ADARM | Pre-Rx | 57 | |
| ADARM | Post-Rx | -300 | |
| HSYQE | Pre-Rx | 50 | |
| HSYQE | Post-Rx | -235 | |
| KTGQF | Pre-Rx | 184 | |
| KTGQF | Post-Rx | -202 | |
|
| |||
| Epitope-Specific Serum (kappa + lambda) Signal: | |||
|
| |||
| ADARM | Pre-Rx | 4 | |
| ADARM | Post-Rx | -2,983 | |
| HSYQE | Pre-Rx | 124 | |
| HSYQE | Post-Rx | -2,610 | |
| KTGQF | Pre-Rx | 4 | |
| KTGQF | Post-Rx | -2,917 | |
|
| |||
| ADARM before Treatment: | ADARM after Treatment: | ||
|
| |||
| KL | 109,081 | KL | -74,585,187 |
| E/KL | 0.000518 | E/KL | -0.000004 |
| x 1 million | 518 | x 1 million | -4 |
|
| |||
| HSYQE before Treatment: | HSYQE after Treatment: | ||
|
| |||
| KL | 3,108,981 | KL | -310,898 |
| E/KL | 0.399997 | E/KL | -0.089922 |
| x 1 million | 399,997 | x 1 million | -89,922 |
|
| |||
| KTGQF before Treatment: | KTGQF after Treatment: | ||
|
| |||
| KL | 109,081 | KL | -2,917 |
| E/KL | 0.001688 | E/KL | -5,045,294 |
| x 1 million | 1,688 | x 1 million | -5,045,294,317,426 |
Two weeks following initiation of peptide-based MS therapy. Test data end-results were similar to those illustrated in Table 4. Formula to Estimate MS Activity Factor (MSAF) = Net IgE/Net KL x 1,000,000. KL = specific (kappa + lambda) signal x 25,000 (Compensates for 1/25,000 serum dilution).